Search results
Results from the WOW.Com Content Network
Abbott Laboratories (ABT) on Wednesday began a recall of approximately 359 million blood-sugar test strips for diabetics. The strips, which are Abbott's Precision Xtra, Precision Xceed Pro ...
FDA's role under the guidelines is to monitor company recalls and assess the adequacy of a firm's action. After a recall is completed, FDA makes sure that the product is destroyed or suitably reconditioned and investigates why the product was defective. Generally, FDA accepts reports and other necessary recall information submitted by e-mail.
A drug recall removes a prescription or over-the-counter drug from the market. Drug recalls in the United States are made by the FDA or the creators of the drug when certain criteria are met. When a drug recall is made, the drug is removed from the market and potential legal action can be taken depending on the severity of the drug recall. [1]
Generic drug manufacturers often change the way in which prescription drug ingredients are made in order to lower costs of making them, so this kind of contamination may be more widespread and undetected in generic drugs. [21] 2022–2023 United States P. aeruginosa outbreak in eye drops
A food company known for popular grocery store condiments has recalled a package of tortilla strips that may be contaminated with wheat, the U.S. Food and Drug Administration said Friday.
That being said, Costco just added two more items to the growing list of product recalls, and you might want to check your freezer if you’ve just finished your weekly grocery haul.
Glucose-elevating agents are medications used to treat hypoglycemia (low blood sugar) by raising blood glucose. In diabetics, hypoglycemia can occur as a result of too much insulin or antidiabetic medication , insufficient food intake, or sudden increase in physical activity or exercise.
LifeScan was established in 1981. [3] It was acquired by Johnson & Johnson (J&J) in 1986, [2] [4] and in June 2018, J&J agreed to sell LifeScan to Platinum Equity as part of its strategic exit from the diabetes device market, accepting an offer originally tendered in March 2018. [1]